
Bayer, which is one of the world's largest pharmaceutical companies, has become the latest partner of contract research and biotech company Gubra.
On Monday, the biotech company reported that it had entered into a sales and licensing agreement with Bayer, which could secure it up to USD 253m in the form of an upfront payment and future milestone payments, provided a number of development and commercial goals are met.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app